Myeloid-derived Growth Factor in Diseases: Structure, Function and Mechanisms

Overview

Journal Mol Med

Publisher Biomed Central

Specialties General Medicine
Molecular Biology

Date 2024 Jul 19

PMID 39030488

Authors

Peng Chen

Xiaohui Huang

Weiwen Li

Weixing Wen

Yue Cao

Jiahuan Li

Yuli Huang

Yunzhao Hu

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived growth factor (MYDGF) is a novel secreted protein with potent antiapoptotic and tissue-repairing properties that is present in nearly 140 human tissues and cell lines, with the highest abundance in the oral epithelium and skin. Initially, MYDGF was found in bone marrow-derived monocytes and macrophages for cardioprotection and repair after myocardial infarction. Subsequent studies have shown that MYDGF plays an important role in other cardiovascular diseases (e.g., atherosclerosis and heart failure), metabolic disorders, renal disease, autoimmune/inflammatory disorders, and cancers. Although the underlying mechanisms have not been fully explored, the role of MYDGF in health and disease may involve cell apoptosis and proliferation, tissue repair and regeneration, anti-inflammation, and glycolipid metabolism regulation. In this review, we summarize the current progress in understanding the role of MYDGF in health and disease, focusing on its structure, function and mechanisms. The graphical abstract shows the current role of MYDGF in different organs and diseases (Fig. 1).

References

Pflanz S, Timans J, Cheung J, Rosales R, Kanzler H, Gilbert J . IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002; 16(6):779-90. DOI: 10.1016/s1074-7613(02)00324-2. View

Bailey M, Lacey D, de Kok B, Veith P, Reynolds E, Hamilton J . Extracellular proteomes of M-CSF (CSF-1) and GM-CSF-dependent macrophages. Immunol Cell Biol. 2010; 89(2):283-93. DOI: 10.1038/icb.2010.92. View

Weeraphan C, Diskul-Na-Ayudthaya P, Chiablaem K, Khongmanee A, Chokchaichamnankit D, Subhasitanont P . Effective enrichment of cholangiocarcinoma secretomes using the hollow fiber bioreactor culture system. Talanta. 2012; 99:294-301. DOI: 10.1016/j.talanta.2012.05.054. View

Liu W, Zhou L, Zhou C, Zhang S, Jing J, Xie L . GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation. Nat Commun. 2016; 7:12794. PMC: 5036163. DOI: 10.1038/ncomms12794. View

Ding Y, Xu X, Meng B, Wang L, Zhu B, Guo B . Myeloid-derived growth factor alleviates non-alcoholic fatty liver disease alleviates in a manner involving IKKβ/NF-κB signaling. Cell Death Dis. 2023; 14(6):376. PMC: 10293205. DOI: 10.1038/s41419-023-05904-y. View

Wang J, Ma R, Wang Y, Zhang S, Wang J, Zheng J . rhMYDGF Alleviates I/R-induced Kidney Injury by Inhibiting Inflammation and Apoptosis via the Akt Pathway. Transplantation. 2023; 107(8):1729-1739. PMC: 10358439. DOI: 10.1097/TP.0000000000004497. View

Wang X, Mao J, Zhou T, Chen X, Tu H, Ma J . Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. Theranostics. 2021; 11(1):209-221. PMC: 7681097. DOI: 10.7150/thno.49327. View

Wang P, Mariman E, Keijer J, Bouwman F, Noben J, Robben J . Profiling of the secreted proteins during 3T3-L1 adipocyte differentiation leads to the identification of novel adipokines. Cell Mol Life Sci. 2004; 61(18):2405-17. PMC: 11138943. DOI: 10.1007/s00018-004-4256-z. View

Hu K, Olsen B . Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. J Clin Invest. 2016; 126(2):509-26. PMC: 4731163. DOI: 10.1172/JCI82585. View

10.

Almagro Armenteros J, Tsirigos K, Sonderby C, Petersen T, Winther O, Brunak S . SignalP 5.0 improves signal peptide predictions using deep neural networks. Nat Biotechnol. 2019; 37(4):420-423. DOI: 10.1038/s41587-019-0036-z. View

11.

Zhou L, Chen J, Li Z, Li X, Hu X, Huang Y . Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One. 2011; 5(12):e15224. PMC: 3013074. DOI: 10.1371/journal.pone.0015224. View

12.

Lu Y, Liao X, Wang T, Hong X, Li Z . The Clinical Relevance and Tumor Promoting Function of C19orf10 in Kidney Renal Clear Cell Carcinoma. Front Oncol. 2021; 11:725959. PMC: 8451477. DOI: 10.3389/fonc.2021.725959. View

13.

Yuan Z, Tsou Y, Zhang X, Huang S, Yang Y, Gao M . Injectable Citrate-Based Hydrogel as an Angiogenic Biomaterial Improves Cardiac Repair after Myocardial Infarction. ACS Appl Mater Interfaces. 2019; 11(42):38429-38439. DOI: 10.1021/acsami.9b12043. View

14.

Du P, Wang T, Wang H, Yang M, Yin H . Mucin-fused myeloid-derived growth factor (MYDGF164) exhibits a prolonged serum half-life and alleviates fibrosis in chronic kidney disease. Br J Pharmacol. 2022; 179(16):4136-4156. DOI: 10.1111/bph.15851. View

15.

He M, Li Y, Wang L, Guo B, Mei W, Zhu B . MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease. Diabetologia. 2020; 63(9):1916-1931. DOI: 10.1007/s00125-020-05197-2. View

16.

Weiler T, Du Q, Krokhin O, Ens W, Standing K, El-Gabalawy H . The identification and characterization of a novel protein, c19orf10, in the synovium. Arthritis Res Ther. 2007; 9(2):R30. PMC: 1906808. DOI: 10.1186/ar2145. View

17.

Ebenhoch R, Akhdar A, Reboll M, Korf-Klingebiel M, Gupta P, Armstrong J . Crystal structure and receptor-interacting residues of MYDGF - a protein mediating ischemic tissue repair. Nat Commun. 2019; 10(1):5379. PMC: 6879528. DOI: 10.1038/s41467-019-13343-7. View

18.

Dasuri K, Antonovici M, Chen K, Wong K, Standing K, Ens W . The synovial proteome: analysis of fibroblast-like synoviocytes. Arthritis Res Ther. 2004; 6(2):R161-8. PMC: 400437. DOI: 10.1186/ar1153. View

19.

Korf-Klingebiel M, Reboll M, Klede S, Brod T, Pich A, Polten F . Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nat Med. 2015; 21(2):140-9. DOI: 10.1038/nm.3778. View

20.

Sim R, Yang C, Yang Y . Chemical Proteomics and Morphological Profiling Revealing MYDGF as a Target for Synthetic Anticancer Macromolecules. Biomacromolecules. 2024; 25(2):1047-1057. DOI: 10.1021/acs.biomac.3c01101. View